Cytosorbents’ (CTSO) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Cytosorbents (NASDAQ:CTSO) in a research note published on Tuesday,Benzinga reports. D. Boral Capital currently has a $10.00 price objective on the medical research company’s stock.

A number of other research analysts have also recently commented on CTSO. HC Wainwright restated a “neutral” rating and set a $1.00 price target on shares of Cytosorbents in a research note on Monday, November 11th. StockNews.com started coverage on Cytosorbents in a report on Saturday, February 22nd. They set a “hold” rating for the company. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $4.67.

Cytosorbents Price Performance

Shares of CTSO stock opened at $1.07 on Tuesday. The company has a market capitalization of $58.51 million, a P/E ratio of -2.97 and a beta of 0.61. The company has a current ratio of 1.97, a quick ratio of 1.58 and a debt-to-equity ratio of 1.06. Cytosorbents has a 12 month low of $0.70 and a 12 month high of $1.61. The stock has a 50 day moving average of $1.03 and a two-hundred day moving average of $1.04.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in CTSO. Sargent Investment Group LLC increased its stake in shares of Cytosorbents by 13.4% in the 3rd quarter. Sargent Investment Group LLC now owns 1,626,247 shares of the medical research company’s stock valued at $2,439,000 after acquiring an additional 192,747 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company’s stock valued at $701,000 after purchasing an additional 32,415 shares in the last quarter. Skylands Capital LLC grew its position in shares of Cytosorbents by 1.0% in the 4th quarter. Skylands Capital LLC now owns 2,781,622 shares of the medical research company’s stock valued at $2,531,000 after purchasing an additional 26,195 shares during the period. Raymond James Financial Inc. acquired a new stake in Cytosorbents during the 4th quarter worth approximately $99,000. Finally, Renaissance Technologies LLC lifted its stake in Cytosorbents by 10.6% in the fourth quarter. Renaissance Technologies LLC now owns 88,020 shares of the medical research company’s stock valued at $80,000 after buying an additional 8,400 shares in the last quarter. Institutional investors and hedge funds own 32.87% of the company’s stock.

Cytosorbents Company Profile

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.